A Dexcom (NSDQ:DXCM) communication on its website states that it will soon cease manufacturing for its G6 continuous glucose ...
First-ever automated insulin delivery with the tubeless Omnipod Insulin Management System and personal smartphone control Initially compatible with Dexcom G6 CGM, with no fingersticks* required ...
DexCom (NASDAQ:DXCM) underwent analysis by 6 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The table below provides a snapshot of their recent ratings, ...
The Non-Insured Health Benefits (NIHB) program establishes exemplary coverage for Dexcom’s real-time continuous glucose monitoring system – bringing game-changing technology to more First Nations and ...
DexCom announced that Chairman and CEO Kevin R. Sayer has taken a temporary medical leave as of September 14, 2025, with President and COO Jacob S. Leach appointed interim CEO and Mark Foletta as ...
DexCom has enormous runway for growth, not just in its home market - the U.S., but internationally as well. Manufacturing efficiencies could support their international ambitions while supporting ...
Dexcom, a global leader in real time continuous glucose monitoring for people with diabetes, is releasing the Dexcom G6 mobile app in Spanish, available immediately for users with a compatible iOS (v1 ...
MADRID--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), the leader in continuous glucose monitoring (CGM), announced today the Dexcom G6 CGM System has received the CE Mark for use during pregnancy in ...
Dexcom G6 gives people with diabetes the power to manage their condition without fingersticks* or scanning Proven to improve glycemic control and can reduce the risk of costly long-term ...
"We are thrilled to offer the Dexcom G6 Continuous Glucose Monitoring (CGM) System to Canadians and are proud of this innovative technology that enables more effective diabetes management," said Laura ...
Zacks Investment Research on MSN
Here's why you should hold DexCom stock in your portfolio for now
DexCom, Inc. DXCM is well-poised for growth in the coming quarters, backed by a huge potential in the continuous glucose ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback